Humanigen to Present at Jefferies Healthcare Conference
May 19 2021 - 7:00AM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical
stage biopharmaceutical company focused on preventing and treating
an immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab™, today announced that the Company’s
management team will participate in a fireside chat at the
Jefferies Healthcare Conference being held from June 1-4, 2021.
Management will discuss its lead product, lenzilumab, which
recently completed a Phase 3 clinical trial of in patients
hospitalized with COVID-19, including the publication of the
results of the trial and the status of the Company’s submission for
Emergency Use Authorization (EUA) to the U.S. Food and Drug
Administration, in addition to providing an update on the Company’s
commercial preparation efforts for lenzilumab, and an overview of
the Company’s other development programs.
Details for the upcoming webcast is below:
Jefferies Healthcare Conference
Live Fireside Chat Date: Wednesday, June 2,
2021 Time: 4:00 PM ET Link:
https://wsw.com/webcast/jeff174/hgen/1834542
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. Humanigen’s immediate focus is on the
development of lenzilumab as a therapy for hospitalized, hypoxic
COVID-19 patients. Humanigen recently announced plans to initiate a
randomized, multicenter, potentially registrational, Phase 2 study
to evaluate the efficacy and safety of lenzilumab combined with all
commercially available CD19 CAR-T therapies in diffuse large B-cell
lymphoma.
Humanigen is also focused on creating next-generation
combinatory gene-edited CAR-T therapies using strategies to improve
efficacy while employing GM-CSF gene knockout technologies to
control toxicity. In addition, Humanigen is developing its own
portfolio of proprietary first-in-class EphA3-CAR-T for various
solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Humanigen is also exploring the effectiveness of its GM-CSF
neutralization technologies (either through the use of lenzilumab
as a neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding Humanigen’s beliefs relating to
the technologies in Humanigen’s current pipeline.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
our lack of profitability and potential need for additional capital
to grow our business; our dependence on partners to further the
development of our product candidates; the uncertainties inherent
in the development, attainment of the requisite regulatory
authorizations and approvals and launch of any new pharmaceutical
product; the outcome of pending or future litigation; and the
various risks and uncertainties described in the "Risk Factors"
sections and elsewhere in Humanigen's periodic and other filings
with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. We
undertake no obligation to revise or update any forward-looking
statements made in this presentation to reflect events or
circumstances after the date hereof, to reflect new information or
the occurrence of unanticipated events, to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, in each case, except as required by
law
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210519005288/en/
Humanigen Media Grace Catlett RXMD gcatlett@rxmedyn.com
516-318-8563
Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024